• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

    7/25/24 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ISPC alert in real time by email

    LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024.

    The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO.

    Event:iSpecimen Second Quarter 2024 Results Conference Call
      
    Date:Tuesday, August 6, 2024
      
    Time:8:30 a.m. Eastern Time
      
    Live Call:+1-800-717-1738 (U.S. Toll Free) or +1-646-307-1865 (International)
      
    Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1680345&tp_key=2f4ff16577
      

    For interested individuals unable to join the conference call, a replay will be available through August 20, 2024, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 1170973. An archived version of the webcast will also be available on iSpecimen's Investor Relations site: https://investors.ispecimen.com/presentations/.

    About iSpecimen

    iSpecimen (NASDAQ:ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

    Forward Looking Statements

    This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

    Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

    Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    For further information, please contact:

    Investor Contact

    KCSA Strategic Communications

    Phil Carlson

    212-896-1233

    [email protected]



    Primary Logo

    Get the next $ISPC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPC

    DatePrice TargetRatingAnalyst
    1/4/2022$20.00Buy
    Craig-Hallum
    11/22/2021$10.00 → $12.00Buy
    EF Hutton
    More analyst ratings

    $ISPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform

    Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ:ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability.Milestone 1 focused on enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack's next-generation, cloud-native architecture, expected to deliver immediate value through:Infrastructure-as-Code (IaC): bui

    8/21/25 8:00:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow

    Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ:ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.iSpecimen has retained WestPark Capital to advise on the initiative with any funds that may be allocated or raised to be earmarked for building a digital asset treasury that will support long-term value creation and fuel innovation across iSpecimen's digital infrastructure. To

    8/7/25 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market

    WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR

    8/4/25 6:45:12 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig-Hallum initiated coverage on iSpecimen with a new price target

    Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00

    1/4/22 7:34:53 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EF Hutton reiterated coverage on iSpecimen with a new price target

    EF Hutton reiterated coverage of iSpecimen with a rating of Buy and set a new price target of $12.00 from $10.00 previously

    11/22/21 11:51:50 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iSpecimen Inc. (0001558569) (Filer)

    8/21/25 8:00:35 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-1 filed by iSpecimen Inc.

    S-1 - iSpecimen Inc. (0001558569) (Filer)

    8/20/25 3:40:43 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by iSpecimen Inc.

    10-Q - iSpecimen Inc. (0001558569) (Filer)

    8/14/25 4:05:51 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Financials

    Live finance-specific insights

    View All

    iSpecimen Reports Second Quarter 2024 Results

    Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024. "iSpecimen's strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for

    8/6/24 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

    LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Second Quarter 2024 Results Conference Call  Date:Tuesday, August 6, 2024  Time:8:30 a.m. Eastern Time  Live Call:+1-800-717-1738

    7/25/24 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Reports First Quarter 2024 Results

    LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. "iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond," said Tracy Curley, C

    5/7/24 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Leadership Updates

    Live Leadership Updates

    View All

    iSpecimen Appoints Eric Langlois as Chief Revenue Officer

    LEXINGTON, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it appointed Eric Langlois as Chief Revenue Officer, effective immediately. Mr. Langlois previously served as the Company's Senior Vice President of Sales and Business Development. In this new role, Mr. Langlois will manage a restructured commercial team aimed at executing on Company initiatives to better align customer needs, streamline collaboration, support innovation and productivity necessary for driving sca

    1/24/23 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Names Tracy Curley as Chief Executive Officer

    LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. "I am grateful to the Board and the entire team at iSpecimen for their support over the past four months, and for the confidence they have shown in my ability to lead the Company," said Tracy Curley, CEO of iSpecimen. "The progress we've made this year in terms of operational and financial execution is encouragi

    1/10/23 1:11:01 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Appoints Joseph J. Basile to Board of Directors

    LEXINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Joseph J. Basile to iSpecimen's Board of Directors (the "Board"), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Mr. Basile is replacing Margaret H. Lawrence as an independent director. Mr. Basile is a sought-after strategic advisor, an accomplished business leader, a skilled negotiator, a trained mediato

    12/5/22 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Liang Yuying

    3 - iSpecimen Inc. (0001558569) (Issuer)

    1/30/25 4:05:21 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Lim Robert Bradley

    3 - iSpecimen Inc. (0001558569) (Issuer)

    12/13/24 6:30:47 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Dhaliwal Avtar

    3 - iSpecimen Inc. (0001558569) (Issuer)

    9/30/24 6:01:18 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

    2/13/24 5:17:07 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D filed by iSpecimen Inc.

    SC 13D - iSpecimen Inc. (0001558569) (Subject)

    4/17/23 1:27:18 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

    2/13/23 4:04:55 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care